Developing breakthrough AXL therapeutics to improve patients' lives

Background

Rights issue 2023

Old woman

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections

Recent News

5th June 2023

BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO

30th May 2023

BerGenBio to Participate in Investor Webcast and Q&A

30th May 2023

BerGenBio ASA: Receipt of subscription rights in the rights issue by primary insiders and their close associates

30th May 2023

BerGenBio ASA - Commencement of the subscription period for the rights issue

26th May 2023

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue

25th May 2023

BerGenBio Announces Abstracts Accepted for Presentation at 2023 ASCO

23rd May 2023

BGBIO – Ex. subscription rights today

22nd May 2023

BerGenBio ASA: Annual general meeting held

20th May 2023

BerGenBio ASA – Updated key information relating to the preferential rights issue